Two Sigma Advisers’s Eli Lilly LLY Stock Holding History

Two Sigma Advisers’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,380	Closed	-$5.78M	–	1189
2025 Q4	$5.78M	Sell	5,380 -207,620	-97%	-$199M	0.01%	742
2025 Q3	$163M	Buy	213,000 +189,500	+806%	+$141M	0.33%	78
2025 Q2	$18.3M	Sell	23,500 -135,200	-85%	-$105M	0.04%	357
2025 Q1	$131M	Sell	158,700 -643,700	-80%	-$536M	0.3%	74
2024 Q4	$619M	Buy	802,400 +266,400	+50%	+$221M	1.43%	7
2024 Q3	$475M	Sell	536,000 -215,900	-29%	-$194M	1.11%	15
2024 Q2	$681M	Buy	751,900 +150,000	+25%	+$120M	1.52%	6
2024 Q1	$468M	Buy	601,900 +161,400	+37%	+$115M	1.08%	14
2023 Q4	$257M	Sell	440,500 -245,400	-36%	-$143M	0.6%	31
2023 Q3	$368M	Buy	685,900 +633,100	+1,199%	+$326M	0.94%	16
2023 Q2	$24.8M	Sell	52,800 -126,800	-71%	-$53.2M	0.06%	270
2023 Q1	$61.7M	Sell	179,600 -142,100	-44%	-$47.9M	0.16%	127
2022 Q4	$118M	Buy	321,700 +233,700	+266%	+$82.9M	0.33%	63
2022 Q3	$28.5M	Sell	88,000 -324,100	-79%	-$103M	0.08%	244
2022 Q2	$134M	Sell	412,100 -656,900	-61%	-$197M	0.38%	60
2022 Q1	$306M	Sell	1,069,000 -707,000	-40%	-$182M	0.81%	20
2021 Q4	$491M	Sell	1,776,000 -249,500	-12%	-$63.2M	1.23%	5
2021 Q3	$468M	Buy	2,025,500 +1,995,800	+6,720%	+$493M	1.21%	6
2021 Q2	$6.82M	Sell	29,700 -14,616	-33%	-$2.94M	0.02%	718
2021 Q1	$8.28M	Sell	44,316 -149,100	-77%	-$29.2M	0.02%	643
2020 Q4	$32.7M	Sell	193,416 -1,893,900	-91%	-$283M	0.09%	240
2020 Q3	$309M	Sell	2,087,316 -302,800	-13%	-$46.9M	0.88%	17
2020 Q2	$392M	Buy	2,390,116 +1,003,200	+72%	+$154M	1.15%	11
2020 Q1	$192M	Sell	1,386,916 -268,700	-16%	-$36.9M	0.74%	16
2019 Q4	$218M	Buy	1,655,616 +360,700	+28%	+$41.8M	0.5%	41
2019 Q3	$145M	Buy	1,294,916 +258,300	+25%	+$28.8M	0.35%	70
2019 Q2	$115M	Buy	1,036,616 +327,100	+46%	+$38.5M	0.29%	86
2019 Q1	$92.1M	Buy	709,516 +180,516	+34%	+$22M	0.23%	105
2018 Q4	$61.2M	Sell	529,000 -326,095	-38%	-$36.4M	0.17%	159
2018 Q3	$91.8M	Sell	855,095 -453,100	-35%	-$45.3M	0.22%	124
2018 Q2	$112M	Sell	1,308,195 -492,500	-27%	-$40.5M	0.3%	77
2018 Q1	$139M	Buy	1,800,695 +1,518,468	+538%	+$122M	0.38%	53
2017 Q4	$23.8M	Buy	282,227 +80,932	+40%	+$6.89M	0.06%	361
2017 Q3	$17.2M	Sell	201,295 -15,300	-7%	-$1.25M	0.05%	412
2017 Q2	$17.8M	Sell	216,595 -228,479	-51%	-$18.6M	0.06%	363
2017 Q1	$37.4M	Buy	445,074 +383,411	+622%	+$30.7M	0.12%	214
2016 Q4	$4.54M	Buy	+61,663	New	+$4.59M	0.02%	778
2016 Q3	–	Sell	-55,368	Closed	-$4.36M	–	2265
2016 Q2	$4.36M	Sell	55,368 -375,300	-87%	-$28.3M	0.02%	597
2016 Q1	$31M	Buy	+430,668	New	+$32.6M	0.17%	149
2015 Q4	–	Sell	-33,939	Closed	-$2.84M	–	1952
2015 Q3	$2.84M	Buy	+33,939	New	+$2.87M	0.02%	633
2015 Q2	–	Sell	-4,512	Closed	-$328K	–	1986
2015 Q1	$328K	Buy	+4,512	New	+$321K	﹤0.01%	1539
2014 Q4	–	Sell	-7,880	Closed	-$511K	–	2612
2014 Q3	$511K	Buy	+7,880	New	+$499K	﹤0.01%	1525
2014 Q1	–	Sell	-674,180	Closed	-$37.6M	–	2411
2013 Q4	$34.4M	Buy	674,180 +388,668	+136%	+$19.5M	0.33%	58
2013 Q3	$14.4M	Buy	285,512 +55,416	+24%	+$2.9M	0.17%	129
2013 Q2	$11.3M	Buy	+230,096	New	+$12.5M	0.16%	119

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Two Sigma Advisers's LLY Position: Q1 2026 in Review

Two Sigma Advisers sold out of Eli Lilly (LLY) in Q1 2026, closing a stake of 5,380 shares — an estimated $5.78M sold.

Two Sigma Advisers first reported a position in LLY in Q2 2013 and held it in 45 quarters. The position peaked at $681M in Q2 2024. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

Two Sigma Advisers reported no remaining Eli Lilly position as of Q1 2026 after selling out during the quarter.
Two Sigma Advisers sold 5,380 Eli Lilly shares in Q1 2026, an estimated $5.78M.
Two Sigma Advisers first reported a position in Eli Lilly in Q2 2013 and held it in 45 quarters.
Two Sigma Advisers's Eli Lilly position peaked at $681M in Q2 2024.
4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.